- Home
- RRGB vs CUE Comparison
RRGB vs CUE Comparison
Compare RRGB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- CUE
- Stock Information
- Founded
- RRGB 1969
- CUE 2014
- Country
- RRGB United States
- CUE United States
- Employees
- RRGB N/A
- CUE N/A
- Industry
- RRGB Restaurants
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- CUE Health Care
- Exchange
- RRGB Nasdaq
- CUE Nasdaq
- Market Cap
- RRGB 88.7M
- CUE 48.0M
- IPO Year
- RRGB 2002
- CUE 2018
- Fundamental
- Price
- RRGB $6.60
- CUE $0.68
- Analyst Decision
- RRGB Strong Buy
- CUE Strong Buy
- Analyst Count
- RRGB 4
- CUE 3
- Target Price
- RRGB $11.88
- CUE $3.00
- AVG Volume (30 Days)
- RRGB 514.5K
- CUE 313.6K
- Earning Date
- RRGB 08-21-2025
- CUE 08-13-2025
- Dividend Yield
- RRGB N/A
- CUE N/A
- EPS Growth
- RRGB N/A
- CUE N/A
- EPS
- RRGB N/A
- CUE N/A
- Revenue
- RRGB $1,252,370,000.00
- CUE $7,991,000.00
- Revenue This Year
- RRGB $0.04
- CUE N/A
- Revenue Next Year
- RRGB N/A
- CUE $23.84
- P/E Ratio
- RRGB N/A
- CUE N/A
- Revenue Growth
- RRGB N/A
- CUE 13.83
- 52 Week Low
- RRGB $2.50
- CUE $0.45
- 52 Week High
- RRGB $7.05
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- RRGB 69.30
- CUE 47.91
- Support Level
- RRGB $5.41
- CUE $0.65
- Resistance Level
- RRGB $6.89
- CUE $0.71
- Average True Range (ATR)
- RRGB 0.43
- CUE 0.08
- MACD
- RRGB 0.08
- CUE 0.00
- Stochastic Oscillator
- RRGB 94.55
- CUE 38.62
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.